公开(公告)号：WO2011130152A3

公开(公告)日：2012-02-23

申请号：PCT/US2011031906

申请日：2011-04-11

Applicant: ACADEMIA SINICA ,  CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  WEI CHUN-YU

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  WEI CHUN-YU

IPC: G01N33/53 ,  C40B30/04 ,  C40B40/10 ,  G01N33/15 ,  G01N33/60

CPC classification number: G01N33/56977

Abstract: A method for identifying from an HLA library an HLA complex that specifically binds to a compound. This method can be relied on to assess whether a compound is likely to induce an adverse drug reaction and, if so, in which human population.

Abstract translation: 从HLA文库鉴定特异性结合化合物的HLA复合物的方法。 可以依靠这种方法来评估化合物是否有可能引起不良药物反应，如果是这样，则可以在哪一种人群中。

公开(公告)号：WO2007134235A3

公开(公告)日：2008-01-17

申请号：PCT/US2007068782

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC ,  CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

CPC classification number: C12Q1/6881 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/142 ,  C12Q2600/156 ,  C12Q2600/16 ,  C12Q2600/172 ,  Y10T436/143333

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

Abstract translation: 本发明涉及确定某些HLA等位基因如HLA-B * 1502或HLA-B * 5801的存在的方法以及用于实施该方法的试剂盒。 还公开了一种基于遗传标记（例如HLA-B）的存在或不存在来评估患者是否处于发展不良药物反应（例如，史蒂文斯 - 约翰逊综合征，中毒性表皮坏死松解症或超敏反应综合征）的风险中的方法 * 1502，HLA-B * 5801或HLA-B * 4601）。

公开(公告)号：WO2005123958A2

公开(公告)日：2005-12-29

申请号：PCT/US2005020483

申请日：2005-06-10

Applicant: ACADEMIA SINICA ,  CHEN YUAN-TSONG ,  WU JER-YUARN ,  HWU WHU-LIANG ,  FANN CATHY S ,  YANG CHI-FAN

Inventor： CHEN YUAN-TSONG ,  WU JER-YUARN ,  HWU WHU-LIANG ,  FANN CATHY S ,  YANG CHI-FAN

IPC: A61K38/17 ,  C07H21/04 ,  C07K14/705 ,  C07K14/74 ,  C12Q1/68

CPC classification number: C12Q1/6883 ,  C07K14/70596 ,  C12Q2600/156

Abstract: We present information obtained from the occurrence of psoriasis and its related disease pityriasis rubra pilaris (PRP) in a large, five-generation kindred. Using a genome-wide scan and single nucleotide polymorphism (SNP) fine mapping, the psoriasis/PRP locus was mapped to chromosome 17q terminus, a region close to but distinct from the 17q PSOR2 locus. Moreover, we sequenced the candidate genes in this region, and identified CD7 as the susceptibility gene in this family. Other genetic markers that co-segregate, such as mutations in the FLJ31528 gene, also indicate susceptibility to psoriasis and PRP. Accordingly, compositions and methods of use are provided for the prediction, diagnosis, disease monitoring and therapeutic development of psoriasis and pityriasis rubra pilaris (PRP).

Abstract translation: 我们提供从大型五代亲属中发现的牛皮癣及其相关疾病糠疹糠疹（PRP）发生的信息。 使用全基因组扫描和单核苷酸多态性（SNP）精细定位，牛皮癣/ PRP基因座被映射到染色体17q末端，这是接近但不同于17q PSOR2基因座的区域。 此外，我们对该区域的候选基因进行了测序，并将CD7鉴定为该家族的易感基因。 共分离的其他遗传标记，如FLJ31528基因中的突变，也表明易感银屑病和PRP。 因此，提供了组合物和使用方法用于牛皮癣和糠疹糠疹（PRP）的预测，诊断，疾病监测和治疗发展。

公开(公告)号：AU2013370009B2

公开(公告)日：2016-11-17

申请号：AU2013370009

申请日：2013-12-31

Applicant: ACADEMIA SINICA ,  DCB USA LLC ,  DEV CT BIOTECHNOLOGY

Inventor： LAI JIANN-SHIUN ,  WANG HUNG-LING ,  HUANG CHAO-YANG ,  LOK YING-YUNG ,  CHEN YUAN-TSONG ,  CHAN WOAN-ENG ,  HU CHIH-YOUNG

IPC: C07K16/18 ,  A61K39/395

Abstract: An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO: 195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.

公开(公告)号：CA2651954C

公开(公告)日：2014-02-25

申请号：CA2651954

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68 ,  C12P19/34 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/543

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

公开(公告)号：PT2016198E

公开(公告)日：2013-07-29

申请号：PT07797432

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

公开(公告)号：DK2016198T3

公开(公告)日：2013-07-15

申请号：DK07797432

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

公开(公告)号：AU2007249225B2

公开(公告)日：2013-06-27

申请号：AU2007249225

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHANG CHI-FENG ,  HUNG SHUEN-LU ,  CHEN WEI-HSUAN ,  CHEN YUAN-TSONG ,  SHEN CHIH-LUNG ,  LIN HSIN-YU

IPC: C12Q1/68

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

公开(公告)号：DK1697539T3

公开(公告)日：2010-11-22

申请号：DK04776718

申请日：2004-06-18

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-IU ,  CHUNG WEN-HUNG ,  WU JER-YUARN

IPC: C12Q1/68 ,  G01N33/94

公开(公告)号：ES2347150T3

公开(公告)日：2010-10-26

申请号：ES04776718

申请日：2004-06-18

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-IU ,  CHUNG WEN-HUNG ,  WU JER-YUARN

IPC: C12Q1/68 ,  G01N33/94

Abstract: Un método para evaluar el riesgo de un paciente de desarrollar una reacción adversa a fármaco en respuesta a un fármaco, que comprende la determinación de la presencia de un alelo HLA-B seleccionado del grupo que consiste en HLA-B*1502, HLA-B*5801 y HLA-B*4601, en el que la presencia del alelo HLA-B es indicativo de un riesgo de desarrollar una reacción adversa a fármaco.